The Danish pharmaceutical giant Novo Nordisk gets the green light for its purchase of three factories from the American contract manufacturer Catalent.
Thus, Novo Nordisk gains much-needed manufacturing capacity in the USA for its bestsellers Ozempic and Wegovy for the treatment of diabetes and obesity.
In a multi-step deal, Novo pays 11.7 billion dollars, approximately 130 billion kronor, for the three factories.
Initially, the American Federal Trade Commission had objections to the deal, as the purchase could negatively affect Novo Nordisk's competitors. But the authority has now dropped the case.
